Papp Maria, Altorjay Istvan, Norman Gary L, Shums Zakera, Palatka Karoly, Vitalis Zsuzsanna, Foldi Ildiko, Lakos Gabriella, Tumpek Judit, Udvardy Miklos L, Harsfalvi Jolan, Fischer Simon, Lakatos Laszlo, Kovacs Agota, Bene Laszlo, Molnar Tamas, Tulassay Zsolt, Miheller Pal, Veres Gabor, Papp Janos, Lakatos Peter Laszlo
2nd Department of Medicine, University of Debrecen, Debrecen, Hungary.
Inflamm Bowel Dis. 2007 Aug;13(8):984-92. doi: 10.1002/ibd.20146.
Antibodies directed against Saccharomyces cerevisiae (ASCA), perinuclear components of neutrophils (pANCA), and porin protein C of Escherichia coli (anti-OmpC) are reported to be associated with disease phenotype and may be of diagnostic importance in inflammatory bowel disease (IBD). Since limited data are available from Eastern Europe, we assessed the above antibodies in Hungarian IBD patients.
In all, 653 well-characterized, unrelated consecutive IBD patients (Crohn's disease [CD]: 558, m/f: 263/295, duration: 8.1 +/- 10.7 years; ulcerative colitis [UC]: 95, m/f: 44/51, duration: 8.9 +/- 9.8 years) and 100 healthy subjects were investigated. Sera were assayed for anti-Omp and ASCA by enzyme-linked immunosorbent assay (ELISA) and ANCA by indirect immunofluorescence assay (IIF). TLR4 and NOD2/CARD15 variants were tested by polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP). Detailed clinical phenotypes were determined by reviewing the medical charts.
Anti-Omp, ASCA, and atypical pANCA antibodies were present in 31.2%, 59.3%, and 13.8% of CD, 24.2%, 13.7%, and 48.5% of UC patients, and in 20%, 16%, and 5.6% of controls, respectively. ASCA and anti-Omp positivity were associated with increased risk for CD (odds ratio OR = 7.65, 95% confidence interval [CI]: 4.37-13.4; OR(Omp) = 1.81, 95% CI: 1.08-3.05). In a logistic regression analysis, anti-Omp and ASCA were independently associated with ileal and noninflammatory disease, but not with a risk for surgery or response to steroids or infliximab. A serology dosage effect was also observed. ASCA and anti-Omp antibodies were associated with NOD2/CARD15, in addition to a gene dosage effect. No associations were found in UC.
Serological markers were useful in the differentiation between CD and UC in an Eastern European IBD cohort. Reactivity to microbial components was associated with disease phenotype and NOD2/CARD15 genotype, further supporting the role of altered microbial sensing in the pathogenesis of CD.
据报道,抗酿酒酵母抗体(ASCA)、中性粒细胞的核周成分抗体(pANCA)以及抗大肠杆菌孔蛋白C抗体(抗OmpC)与疾病表型相关,在炎症性肠病(IBD)中可能具有诊断意义。由于东欧地区的数据有限,我们对匈牙利IBD患者的上述抗体进行了评估。
共调查了653例特征明确、无亲缘关系的连续性IBD患者(克罗恩病[CD]:558例,男/女:263/295例,病程:8.1±10.7年;溃疡性结肠炎[UC]:95例,男/女:44/51例,病程:8.9±9.8年)以及100名健康受试者。采用酶联免疫吸附测定(ELISA)检测血清中的抗Omp和ASCA,采用间接免疫荧光测定(IIF)检测ANCA。通过聚合酶链反应/限制性片段长度多态性(PCR-RFLP)检测TLR4和NOD2/CARD15变异。通过查阅病历确定详细的临床表型。
抗Omp、ASCA和非典型pANCA抗体在CD患者中的阳性率分别为31.2%、59.3%和13.8%,在UC患者中的阳性率分别为24.2%、13.7%和48.5%,在对照组中的阳性率分别为20%、16%和5.6%。ASCA和抗Omp阳性与CD风险增加相关(优势比OR=7.65,95%置信区间[CI]:4.37-13.4;OR(Omp)=1.81,95%CI:1.08-3.05)。在逻辑回归分析中,抗Omp和ASCA与回肠和非炎症性疾病独立相关,但与手术风险、对类固醇或英夫利昔单抗的反应无关。还观察到血清学剂量效应。ASCA和抗Omp抗体与NOD2/CARD15相关,此外还有基因剂量效应。在UC中未发现相关性。
在东欧IBD队列中,血清学标志物有助于区分CD和UC。对微生物成分的反应性与疾病表型和NOD2/CARD15基因型相关,进一步支持了微生物感知改变在CD发病机制中的作用。